2 weeks Ago By ABMN Staff
Caribou Biosciences, Inc. ( NASDAQ:CRBU – Free Report ) – Research analysts at Brookline Capital Management lifted their FY2024 earnings estimates for shares of Caribou Biosciences in a note issued to investors on Wednesday, November 6th. Brookline Capital Management analyst L.
Cann now forecasts that the company will post earnings of ($1.66) per share for the year, up from their prior estimate of ($1.76).
The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.71) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q4 2024 earnings at ($0.
39) EPS, FY2025 earnings at ($2.91) EPS and FY2027 earnings at ($3.80) EPS.
Caribou Biosciences ( NASDAQ:CRBU – Get Free Report ) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.
44) by $0.06. The business had revenue of $2.
02 million during the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.
46% and a negative net margin of 1,290.81%. View Our Latest Analysis on CRBU Caribou Biosciences Trading Down 15.
9 % Shares of CRBU opened at $2.35 on Monday. The stock has a market cap of $212.
34 million, a P/E ratio of -1.58 and a beta of 2.26.
Caribou Biosciences has a 1 year low of $1.50 and a 1 year high of $8.33.
The stock’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $2.27.
Institutional Trading of Caribou Biosciences Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Caribou Biosciences in the 2nd quarter worth $30,000. China Universal Asset Management Co.
Ltd. lifted its holdings in shares of Caribou Biosciences by 63.8% in the third quarter.
China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after purchasing an additional 6,768 shares in the last quarter.
Intech Investment Management LLC acquired a new position in shares of Caribou Biosciences during the third quarter worth about $43,000. Point72 DIFC Ltd grew its holdings in shares of Caribou Biosciences by 389.4% during the second quarter.
Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after buying an additional 23,995 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd.
acquired a new stake in Caribou Biosciences in the 2nd quarter valued at approximately $52,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.
About Caribou Biosciences ( Get Free Report ) Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. Recommended Stories Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
